Login to Your Account



Crescendo Biologics lands $28M to finance dermatology drug R&D

By Nuala Moran
Staff Writer

Monday, December 16, 2013

LONDON – Crescendo Biologics Ltd. has raised £17.5 million (US$28 million) in a Series A funding that will enable it to take antibody technology into a new arena, as the basis of topical treatments for dermatological diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription